Articles Tagged With: Cholesterol
-
The Best Use of Statins in Patients with Coronary Artery Disease
A randomized, multicenter study of high-intensity statin therapy to a treat-to-target approach in coronary artery disease patients showed no difference in three-year outcomes. These results suggest treating to a target may be more suitable to individual patients compared to blanket high-intensity statin use.
-
Improving Statin Tolerance in Elderly Patients
In a post-hoc analysis of the RACING trial, researchers found the combination of moderate-intensity statin and ezetimibe therapy vs. high-intensity statin therapy alone in older subjects resulted in similar reductions in cardiovascular events over three years, but fewer adverse effects with the combination therapy.
-
Moderate-Intensity Exercise OK for Statin Users with Muscle Pain
The go-to drug therapy patients use to lower their bad cholesterol levels can cause muscle pain for some, but researchers found moderate exercise would not exacerbate that pain.
-
Long-Term Statin Use Associated with Lower Stroke Risk
A cohort of Danish patients who were taking the cholesterol control medication were less likely to experience an intracerebral hemorrhage.
-
Triglyceride-Lowering Therapy and Cardiovascular Events
Researchers studied pemafibrate vs. placebo in patients with type 2 diabetes, mild-to-moderate triglyceride elevations, and low levels of HDL and well-controlled LDL cholesterol. Despite a 31% reduction in triglyceride levels, there was no improvement in the risk of cardiovascular outcomes over a median follow-up of 3.4 years.
-
Statins Plus Ezetimibe vs. Statins Alone
A comparison of rosuvastatin 10 mg/day plus ezetimibe (10 mg/day) to 20 mg/day of rosuvastatin alone showed non-inferiority in three-year major cardiovascular outcomes, with lower LDL cholesterol levels and fewer episodes of drug discontinuation or dose reductions in the combination therapy group.
-
Secondary Prevention Statin Adherence and Major Adverse Cardiovascular Events
A study of adherence to statin therapy after an atherosclerotic cardiovascular event demonstrated full adherence for five years was associated with significantly lower major adverse cardiovascular events, although only 5% of these patients achieved full compliance for five years.
-
Inclisiran Injection (Leqvio)
Inclisiran can be prescribed as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who required additional low-density lipoprotein cholesterol lowering.
-
Researchers Observe No Connections Between Statin Therapy, Cognitive Decline
But randomized trials are needed to better detail long-term risk-benefit ratio. -
Another Agent for Hypercholesterolemia
A pooled analysis of three randomized, controlled trials of inclisiran in patients with atherosclerotic cardiovascular disease or its risk equivalent showed impressive reductions in LDL cholesterol with subcutaneous injections every six months.